SXHHF yields 2000000.00% · PFE yields 6.13%● Live data
📍 SXHHF pulled ahead of the other in Year 1
Combined, SXHHF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SXHHF + PFE for your $10,000?
Sonomax Technologies Inc. engages in the development and licensing of intra-ear technology for hearing protection, hearing enhancement, and other auditory applications. The company offers custom-fitted hearing protection and communication enhancement products; and functional accessories, such as Sonomax Self-Fit hearing protection faceplate to support third party acoustic tube radio solutions and Sonomax Quick-Fit lubricant. It also provides SonoPass proof of performance software for validating earpiece performance; and earpiece solutions that are plug and play with multiple radio systems. Sonomax Technologies Inc. sells its products through industrial wholesalers, CE retail distributors, and OEMs primarily in Australia, Canada, Europe, and the United States. The company was formerly known as Sonomax Hearing Healthcare Inc. and changed its name to Sonomax Technologies Inc. in March 2010. The company was founded in 1998 and is headquartered in Montreal, Canada.
Full SXHHF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.